## Rowena A Bull

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7106437/publications.pdf

Version: 2024-02-01

88 papers 4,258 citations

32 h-index 62 g-index

99 all docs 99 docs citations 99 times ranked 5853 citing authors

#	Article	IF	CITATIONS
1	Emergence of a New Norovirus Genotype II.4 Variant Associated with Global Outbreaks of Gastroenteritis. Journal of Clinical Microbiology, 2006, 44, 327-333.	1.8	302
2	Norovirus recombination. Journal of General Virology, 2007, 88, 3347-3359.	1.3	294
3	Norovirus Recombination in ORF1/ORF2 Overlap. Emerging Infectious Diseases, 2005, 11, 1079-1085.	2.0	257
4	Rapid Evolution of Pandemic Noroviruses of the GII.4 Lineage. PLoS Pathogens, 2010, 6, e1000831.	2.1	252
5	Sequential Bottlenecks Drive Viral Evolution in Early Acute Hepatitis C Virus Infection. PLoS Pathogens, 2011, 7, e1002243.	2.1	201
6	Analytical validity of nanopore sequencing for rapid SARS-CoV-2 genome analysis. Nature Communications, 2020, 11, 6272.	5.8	183
7	Epidemics of Gastroenteritis during 2006 Were Associated with the Spread of Norovirus GII.4 Variants 2006a and 2006b. Clinical Infectious Diseases, 2008, 46, 413-420.	2.9	152
8	Mechanisms of GII.4 norovirus evolution. Trends in Microbiology, 2011, 19, 233-240.	3.5	135
9	The Interferon-induced Transmembrane Proteins, IFITM1, IFITM2, and IFITM3 Inhibit Hepatitis C Virus Entry. Journal of Biological Chemistry, 2015, 290, 25946-25959.	1.6	128
10	Linking the T cell receptor to the single cell transcriptome in antigenâ€specific human T cells. Immunology and Cell Biology, 2016, 94, 604-611.	1.0	118
11	Contribution of Intra- and Interhost Dynamics to Norovirus Evolution. Journal of Virology, 2012, 86, 3219-3229.	1.5	109
12	Clonally diverse CD38+HLA-DR+CD8+ T cells persist during fatal H7N9 disease. Nature Communications, 2018, 9, 824.	5.8	107
13	Inhibitors of the Hepatitis C Virus Polymerase; Mode of Action and Resistance. Viruses, 2015, 7, 5206-5224.	1.5	102
14	Viral Quasispecies Assembly via Maximal Clique Enumeration. PLoS Computational Biology, 2014, 10, e1003515.	1.5	93
15	Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Hepatology, 2010, 52, 1564-1572.	3.6	88
16	Norovirus Excretion in an Aged-Care Setting. Journal of Clinical Microbiology, 2008, 46, 2119-2121.	1.8	83
17	Hepatitis C virus reinfection and superinfection among treated and untreated participants with recent infection. Hepatology, 2012, 55, 1058-1069.	3.6	82
18	Norovirus GII.4 Strains and Outbreaks, Australia. Emerging Infectious Diseases, 2007, 13, 1128-1130.	2.0	80

#	Article	IF	CITATIONS
19	Norovirus GII.4 variant 2006b caused epidemics of acute gastroenteritis in Australia during 2007 and 2008. Journal of Clinical Virology, 2010, 49, 265-271.	1.6	77
20	Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell Reports Medicine, 2021, 2, 100228.	3.3	66
21	Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants. Frontiers in Immunology, 2021, 12, 752003.	2.2	62
22	Accurate single nucleotide variant detection in viral populations by combining probabilistic clustering with a statistical test of strand bias. BMC Genomics, 2013, 14, 501.	1.2	61
23	Impact of sequencing depth and read length on single cell RNA sequencing data of T cells. Scientific Reports, 2017, 7, 12781.	1.6	60
24	Next generation deep sequencing and vaccine design: today and tomorrow. Trends in Biotechnology, 2012, 30, 443-452.	4.9	59
25	Respiratory viral co-infections among SARS-CoV-2 cases confirmed by virome capture sequencing. Scientific Reports, 2021, 11, 3934.	1.6	55
26	A method for near full-length amplification and sequencing for six hepatitis C virus genotypes. BMC Genomics, 2016, 17, 247.	1.2	52
27	The Influence of Hepatitis C Virus Genetic Region on Phylogenetic Clustering Analysis. PLoS ONE, 2015, 10, e0131437.	1.1	48
28	Broadly neutralizing antibodies from an individual that naturally cleared multiple hepatitis C virus infections uncover molecular determinants for E2 targeting and vaccine design. PLoS Pathogens, 2019, 15, e1007772.	2.1	45
29	Graphene- and Nanoparticle-Embedded Antimicrobial and Biocompatible Cotton/Silk Fabrics for Protective Clothing. ACS Applied Bio Materials, 2021, 4, 6175-6185.	2.3	39
30	Transmission of Hepatitis C Virus among Prisoners, Australia, 2005–2012. Emerging Infectious Diseases, 2015, 21, 765-774.	2.0	37
31	Higher abundance of enterovirus A species in the gut of children with islet autoimmunity. Scientific Reports, 2019, 9, 1749.	1.6	37
32	Hepatitis C Virus Nonstructural Protein 5B Is Involved in Virus Morphogenesis. Journal of Virology, 2012, 86, 5080-5088.	1.5	35
33	Immunizations with diverse sarbecovirus receptor-binding domains elicit SARS-CoV-2 neutralizing antibodies against a conserved site of vulnerability. Immunity, 2021, 54, 2908-2921.e6.	6.6	35
34	Transmitted/Founder Viruses Rapidly Escape from CD8 <sup>+</sup> T Cell Responses in Acute Hepatitis C Virus Infection. Journal of Virology, 2015, 89, 5478-5490.	1.5	31
35	Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ TÂcell responses. Cell Reports, 2022, 38, 110345.	2.9	30
36	A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice. Frontiers in Immunology, 2019, 10, 1145.	2.2	29

#	Article	IF	CITATIONS
37	Clearance of hepatitis C virus is associated with early and potent but narrowly-directed, Envelope-specific antibodies. Scientific Reports, 2019, 9, 13300.	1.6	28
38	SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays. Viruses, 2021, 13, 247.	1.5	28
39	Comparison of the replication properties of murine and human calicivirus RNA-dependent RNA polymerases. Virus Genes, 2011, 42, 16-27.	0.7	26
40	Sequencing of hepatitis C virus for detection of resistance to directâ€acting antiviral therapy: A systematic review. Hepatology Communications, 2017, 1, 379-390.	2.0	26
41	Genome-Wide Mutagenesis of Dengue Virus Reveals Plasticity of the NS1 Protein and Enables Generation of Infectious Tagged Reporter Viruses. Journal of Virology, 2017, 91, .	1.5	24
42	A molecular transmission network of recent hepatitis C infection in people with and without <scp>HIV</scp> : Implications for targeted treatment strategies. Journal of Viral Hepatitis, 2017, 24, 404-411.	1.0	23
43	Optimized cell systems for the investigation of hepatitis C virus E1E2 glycoproteins. Journal of General Virology, 2021, 102, .	1.3	23
44	Amplification and next generation sequencing of near full-length human enteroviruses for identification and characterisation from clinical samples. Scientific Reports, 2018, 8, 11889.	1.6	22
45	Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies. MAbs, 2021, 13, 1922134.	2.6	22
46	Persistent infections in immunocompromised hosts are rarely sources of new pathogen variants. Virus Evolution, 2017, 3, vex018.	2.2	21
47	B cell immunodominance in primary hepatitis C virus infection. Journal of Hepatology, 2020, 72, 670-679.	1.8	21
48	Understanding the complex evolution of rapidly mutating viruses with deep sequencing: Beyond the analysis of viral diversity. Virus Research, 2017, 239, 43-54.	1.1	19
49	Envelope-Specific IgG3 and IgG1 Responses Are Associated with Clearance of Acute Hepatitis C Virus Infection. Viruses, 2020, 12, 75.	1.5	19
50	Resistance to hepatitis C virus: potential genetic and immunological determinants. Lancet Infectious Diseases, The, 2015, 15, 451-460.	4.6	17
51	Historical Trends in the Hepatitis C Virus Epidemics in North America and Australia. Journal of Infectious Diseases, 2016, 214, 1383-1389.	1.9	16
52	Understanding the Determinants of BnAb Induction in Acute HCV Infection. Viruses, 2018, 10, 659.	1.5	15
53	A method for detecting hepatitis C envelope specific memory B cells from multiple genotypes using cocktail E2 tetramers. Journal of Immunological Methods, 2019, 472, 65-74.	0.6	15
54	Phylogenetic analysis of fullâ€length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC <sup>3</sup> Study. Journal of Viral Hepatitis, 2017, 24, 43-52.	1.0	14

#	Article	IF	CITATIONS
55	Genomic characterization of hepatitis C virus transmitted founder variants with deep sequencing. Infection, Genetics and Evolution, 2019, 71, 36-41.	1.0	14
56	Adaptation of Oxford Nanopore technology for hepatitis C whole genome sequencing and identification of within-host viral variants. BMC Genomics, 2021, 22, 148.	1.2	14
57	Occult infection with hepatitis C virus: friend or foe?. Immunology and Cell Biology, 2012, 90, 763-773.	1.0	13
58	Hepatitis Câ€specific effector and regulatory <scp>CD</scp> 4 Tâ€eell responses are associated with the outcomes of primary infection. Journal of Viral Hepatitis, 2016, 23, 985-993.	1.0	13
59	HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection. Infection, Genetics and Evolution, 2016, 37, 252-258.	1.0	13
60	Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian Prisons. Journal of Clinical Microbiology, 2016, 54, 1855-1861.	1.8	12
61	Dynamic evolution of hepatitis C virus resistance-associated substitutions in the absence of antiviral treatment. Scientific Reports, 2017, 7, 41719.	1.6	12
62	Analysis of resistanceâ€associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents. Journal of Viral Hepatitis, 2017, 24, 37-42.	1.0	11
63	Chemokine-Regulated Recruitment of Antigen-Specific T-Cell Subpopulations to the Liver in Acute and Chronic Hepatitis C Infection. Journal of Infectious Diseases, 2019, 219, 1430-1438.	1.9	11
64	Single molecule, near full-length genome sequencing of dengue virus. Scientific Reports, 2020, 10, 18196.	1.6	11
65	Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for Protection. Frontiers in Cellular and Infection Microbiology, 2019, 9, 91.	1.8	10
66	Rare occurrence of occult hepatitis C virus in apparently uninfected injecting drug users: a twoâ€eentre, masked, case–control study. Journal of Viral Hepatitis, 2013, 20, 725-728.	1.0	9
67	A Bioinformatics Pipeline for the Analyses of Viral Escape Dynamics and Host Immune Responses during an Infection. BioMed Research International, 2014, 2014, 1-12.	0.9	9
68	Limited naturally occurring escape in broadly neutralizing antibody epitopes in hepatitis C glycoprotein E2 and constrained sequence usage in acute infection. Infection, Genetics and Evolution, 2017, 49, 88-96.	1.0	8
69	SARS-CoV-2 N-gene mutation leading to Xpert Xpress SARS-CoV-2 assay instability. Pathology, 2022, , .	0.3	8
70	Getting to the (germinal) center of humoral immune responses to SARS-CoV-2. Cell, 2022, 185, 945-948.	13.5	7
71	Correlation of polymerase replication fidelity with genetic evolution of influenza A/Fujian/411/02(H3N2) viruses. Journal of Medical Virology, 2011, 83, 510-516.	2.5	6
72	Genomic variability of withinâ€host hepatitis C variants in acute infection. Journal of Viral Hepatitis, 2019, 26, 476-484.	1.0	6

#	Article	IF	CITATIONS
73	Optimisation and validation of a new method for antibody dependent cellular phagocytosis in hepatitis C virus infection. Journal of Immunological Methods, 2021, 495, 113087.	0.6	6
74	Viral Quasispecies Assembly via Maximal Clique Enumeration. Lecture Notes in Computer Science, 2014, , 309-310.	1.0	6
75	Conserved epitopes with high HLA-I population coverage are targets of CD8+ T cells associated with high IFN- $\hat{l}^3$ responses against all dengue virus serotypes. Scientific Reports, 2020, 10, 20497.	1.6	5
76	Human CD8 Tâ€stem cell memory subsets phenotypic and functional characterization are defined by expression of CD122 or CXCR3. European Journal of Immunology, 2021, 51, 1732-1747.	1.6	5
77	Hepatitis C Virus Epitope Immunodominance and B Cell Repertoire Diversity. Viruses, 2021, 13, 983.	1.5	5
78	Effect of reassortment on the nucleotide and amino acid changes of human A/H3N2 RNP subunits during 1998–2009. Journal of Clinical Virology, 2011, 51, 270-275.	1.6	4
79	Evidence that hepatitis C virus genome partly controls infection outcome. Evolutionary Applications, 2014, 7, 533-547.	1.5	4
80	Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance. Hepatology Communications, 2020, 4, 904-915.	2.0	4
81	Assessment of Inter-Laboratory Differences in SARS-CoV-2 Consensus Genome Assemblies between Public Health Laboratories in Australia. Viruses, 2022, 14, 185.	1.5	4
82	Persistent highâ€level shedding of cultivable SARSâ€CoVâ€2 Delta virus 33 days after onset of COVIDâ€19 in a hospitalized patient with pneumonia. Journal of Medical Virology, 2022, 94, 4043-4046.	2.5	4
83	Comparison of influenza virus replication fidelity in vitro using selection pressure with monoclonal antibodies. Journal of Medical Virology, 2013, 85, 1090-1094.	2.5	2
84	Erratum to "A Bioinformatics Pipeline for the Analyses of Viral Escape Dynamics and Host Immune Responses during an Infection― BioMed Research International, 2014, 2014, 1-2.	0.9	1
85	Antiâ€envelope antibody responses in highly exposed seronegative individuals may be associated with protection from HCV infection. Journal of Viral Hepatitis, 2020, 27, 1012-1021.	1.0	1
86	Co-evolving mutations in hepatitis C virus in the context of immune escape against neutralising antibody responses - A bioinformatic workflow for the analysis of co-evolving mutations in viral genomes. , $2015,  \ldots$		0
87	Unravelling the complexities of virus and host interactions in the Viral Immunology Systems Program, NHMRC, ACH2, National Institutes of Health. Impact, 2017, 2017, 34-36.	0.0	0
88	Evolution of within-host variants of the hepatitis C virus. Infection, Genetics and Evolution, 2022, 99, 105242.	1.0	0